As the primary component of the amyloid plaques seen in the brains of Alzheimer patients, amyloid- (A) refers to peptides of 36–43 amino acids that are crucially involved in Alzheimer's disease. The amyloid precursor protein (APP), which is cut by specific enzymes to produce A, produces the peptides. Amyloid molecules can group together to create a variety of flexible, soluble oligomers.A amyloid-peptide buildup results from excessive A production or malfunctioning clearance mechanisms. Amyloid- forms diffuse and neuritic plaques in the parenchyma and blood vessels by self-aggregating into oligomers of various sizes. Strong synaptotoxins, proteasome inhibition, mitochondrial inhibition, alteration of intracellular Ca2+ levels, and induction of inflammatory processes are all characteristics of amyloid-oligomers and plaques. Neuronal dysfunction is also thought to be influenced by the loss of A's typical physiological functions.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V71410 | Amyloid β-Protein (1-24) | 138648-77-8 | Amyloid β-Protein (1-24) is a bioactive peptide discovered by peptide screening. |
|
V71419 | Amyloid β-Protein (1-46) | 285554-31-6 | Amyloid β-Protein (1-46) is an Aβ fragment. |
|
V71382 | Amyloid β-Protein (1-6) | 214550-64-8 | Amyloid β-Protein (1-6) is an Aβ fragment. |
|
V71414 | Amyloid β-Protein (16-22) | 153247-41-7 | Amyloid β-Protein (16-22) is an Aβ fragment. |
|
V71381 | Amyloid β-Protein (3-42) | 157884-74-7 | Amyloid β-Protein (3-42) is the precursor of Pyr peptide. |
|
V77942 | Amyloid β-Protein (33-42) (TFA) | Amyloid β-Protein (33-42) TFA is the 33-42 fragment of β-amyloid residues. | |
|
V71426 | Amyloid β-Protein (4-42) | 157884-72-5 | Amyloid β-Protein (4-42) is an Aβ fragment. |
|
V71430 | Amyloid β-Protein (5-42) | 1678415-97-8 | Amyloid β-Protein (5-42) is an Aβ fragment. |
|
V71383 | Amyloid-Forming peptide GNNQQNY | 339091-39-3 | Amyloid-Forming peptide GNNQQNY is a biologically active peptide. |
|
V11347 | Anle138b | 882697-00-9 | Anle138b is a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. |
|
V71368 | Anti-amyloid agent-1 | 1396778-73-6 | Anti-amyloid agent-1 is a potent anti-amyloid compound that can inhibit amyloid aggregation. |
|
V80559 | Antioxidant agent-8 | Antioxidant agent-8 is an orally bioactive Aβ1-42 deposition inhibitor. | |
|
V4637 | ARN2966 | 102212-26-0 | ARN2966 is a novel and potent post-transcriptional modulator of APP (amyloid precursor protein) expression; reduces expression of APP with resultant lower production of Aβ. |
|
V71363 | AZD4694 Precursor (AZ13040214; NAV4614) | 1211333-20-8 | AZD4694 Precursor (AZ13040214) is the precursor of [18F] AZD4694 and is used to synthesize [18F] AZD4694. |
|
V2883 | Azeliragon (TTP488; PF-04494700) | 603148-36-3 | Azeliragon (also known as TTP488 and PF-04494700) is a potent and orally bioavailable RAGE (Receptor for Advanced Glycation End products) inhibitor that has the potential for the treatment ofmild-to-moderate Alzheimers disease and cerebral amyloid angiopathy. |
|
V71395 | Aβ Fibrillization modulator 1 | 2847131-53-5 | Aβ Fibrillization modulator 1 can stabilize Aβ monomer. |
|
V78525 | Aβ-IN-6 | Aβ-IN-6 reduces proinflammatory cytokine release from microglia. | |
|
V78330 | Aβ-IN-7 | Aβ-IN-7 (compound 5a) is a potent inhibitor of Aβ aggregation. | |
|
V78331 | Aβ-IN-8 | Aβ-IN-8 (compound 7e) is a potent inhibitor of Aβ aggregation. | |
|
V71369 | Aβ/tau aggregation-IN-1 | 2252162-81-3 | Aβ/tau aggregation-IN-1 is a potent inhibitor of Aβ1-42 β-sheets formation and tau aggregation. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
